Nội dung của trang này:
Nội dung của trang này:
Tổng quan
Hospital-acquired pneumonia (HAP) is defined as pneumonia
occurring ≥48
hours after admission and excluding any infection that is incubating at the
time of admission, as stated in the Introduction
section.
Hospital-acquired pneumonia is one of the most common causes
of nosocomial infection in hospitalized and intensive care patients, as stated in
the Epidemiology section.
The Pathophysiology section states that hospital-acquired pneumonia develops
from an imbalance of the normal host defenses and the ability of the
microorganism to colonize and invade the lower respiratory tract.
Risk factors for hospital-acquired pneumonia,
ventilator-associated pneumonia and multidrug-resistant pathogens are
enumerated in the Risk Factors section.

History and Physical Examination
The Clinical Presentation section enumerates the typical signs and symptoms of hospital-acquired pneumonia.
Chẩn đoán
The Diagnosis or
Diagnostic Criteria section
features the Clinical Pulmonary Infection Score (CPIS) used to quantify
clinical, radiographic, microbiologic, and physiological findings. This is
important in the clinical decision-making process prior to antibiotic therapy,
assessment of treatment response and antibiotic de-escalation.
Discussion on cultures, microbiologic techniques, and other
tests is in the Laboratory Tests and
Ancillaries section. Chest
x-ray, as an aid in identifying disease severity and the presence of
complications, are discussed in Imaging
section.
Other diseases that can present with the same symptoms as hospital-acquired
pneumonia are listed in the Differential
Diagnosis section.
Xử trí
The CURB65 scoring system for mortality risk assessment is
stated in the Evaluation
section. The need to assess patients for clinical response and other ancillary
procedures during the course of antibiotic treatment and follow-up are also
explained in this section.
Initiation of empiric therapy and choice of antibiotics are
discussed in the Principles of Therapy
section.
The Pharmacological
Therapy section discusses in detail the empiric therapy of
multidrug-resistant pathogen based on the presence or absence of risk factors.
The Nonpharmacological
section explains the supportive therapy in the management of hospital-acquired
pneumonia.
Recommended preventive measures for ventilator-associated
pneumonia are in the Prevention section.
The Monitoring
section discussed follow-up evaluation for patients treated for
hospital-acquired pneumonia based on clinical improvement and response to
therapy.